Dr. Jonathan E. Rosenberg

Dr. Jonathan E. Rosenberg, MD, is a medical oncologist specializing in genitourinary cancers, with particular expertise in urothelial cancers arising from the bladder, ureters, renal pelvis, and urethra. He serves as Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center, a position he has held since 2018. Prior to that role, he served as Section Head for non-prostate genitourinary cancers at MSK, and before joining MSK in 2012, he was Clinical Director of the Genitourinary Oncology Center and Director of the Bladder Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center of Harvard Medical School. His path into oncology was shaped by a personal experience, watching his grandfather live with and ultimately pass away from prostate cancer in the 1980s, which exposed him firsthand to the limited treatment options available at the time and inspired him to pursue a career improving outcomes for patients with genitourinary cancers.

Dr. Rosenberg is a leading figure in the development of immunotherapy and targeted therapy for urothelial cancer. He led the clinical trial that resulted in the first new FDA drug approval for urothelial cancer in more than 20 years, and he served as principal investigator of a subsequent trial that earned FDA Breakthrough Therapy Designation for another agent in this disease. His research focuses on understanding the genetic changes that drive bladder cancer aggressiveness, identifying predictive biomarkers to guide individualized treatment decisions, and testing new strategies that target the cellular processes fueling cancer growth. He leads and participates in multiple clinical trials evaluating chemotherapy, targeted therapy, and immunotherapy, both alone and in combination. His work has materially reshaped treatment standards for patients with advanced urothelial cancer.

Beyond his laboratory and clinical trial work, Dr. Rosenberg places strong emphasis on patient education and shared decision-making, helping patients understand their diagnosis, treatment options, and prognosis from their very first visit. He works within a multidisciplinary team committed to providing comprehensive care across all aspects of oncology. He serves on several national committees dedicated to improving genitourinary cancer treatment and travels widely to present his research at national and international meetings. His career reflects a consistent commitment to translating scientific discovery into meaningful advances for patients with bladder and other urothelial cancers.